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Abstract
Objective Postmenopausal hormone replacement therapy
(HRT) is associated with an increase in breast cancer risk,
which correlates to the duration of HRT use. We wanted to
investigate a possible association between HRT use and the
risk of a histologic subtype of breast cancer.
Patients and methods From 1995 until 2004, 497 cases of
primary ductal, lobular or ductulolobular breast cancer in
postmenopausal women were diagnosed at the Department
of Gynecology and Obstetrics, University Hospital Basel,
Switzerland. The data was derived from patient’s records.
HRT ever use was deWned as HRT use for ¸6 months.
Results Of the 99 cases of lobular cancer 72.7% were
invasive lobular cancers, 21.2% were invasive ductulolobu-
lar cancers and 6.1% were lobular cancers in situ. Of the 398
cases of ductal cancer, 90.5% were invasive ductal cancers
and 9.5% were ductal cancers in situ. Totally 144 women
were HRT ever users, and 341 women were HRT never
users. HRT status could not be deWned in 12 women. HRT
ever use was associated with an increased risk for lobular
cancer (OR 1.67; 95% CI 1.02–2.73). Also, menopause due
to bilateral oophorectomy was associated with an increased
risk for lobular cancer (OR 2.42; 95% CI 1.06–5.54).
Conclusions There is evidence that HRT as well as meno-
pause due to bilateral oophorectomy may be associated
with an increased risk for lobular cancer. This association is
of major clinical relevance, since lobular breast cancer is
more diYcult to diagnose clinically and radiologically than
ductal breast cancer.
Keywords Breast cancer · Histologic subtype · Hormone 
replacement therapy (HRT)
Introduction
Hormone replacement therapy (HRT) [51] is being used to
treat menopausal symptoms caused by the falling levels of
circulating ovarian hormones. Postmenopausal HRT is
associated with an increased breast cancer risk that rises
with the duration of HRT use [1, 4, 5, 16, 33, 45, 50], but
dissipates after its discontinuation [1, 4, 13, 16, 33]. Breast
cancer risk is no longer elevated 5 years after cessation of
HRT, compared to women who never used HRT [1, 4, 13,
16, 33]. Combined estrogens–progestin HRT regimens
increase breast cancer risk beyond the level associated with
estrogens alone [1, 4, 14, 16, 36, 38, 41, 45].
Few previous studies have investigated a possible asso-
ciation between HRT use and the risk of a speciWc histolog-
ical subtype of breast cancer with inconsistent conclusions:
some studies report an elevated risk for lobular breast can-
cer in ever users of HRT [28, 30, 31, 34, 36], while others
found no such association [47].
An increase in lobular breast cancer would be of clinical
relevance since lobular breast cancer is less likely to be
detected by mammography [6, 20, 22, 42, 44], ultrasound
[6, 10, 44] or clinical examination [6, 10, 22, 25, 43] than
ductal breast cancer. Additionally, HRT use is associated
with an increase in breast density, a change which further
hampers the diagnosis of breast cancer [8, 39].
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is important to know if we should expect a higher incidence
of lobular cancer in HRT users.
We conducted this hospital based case study to evaluate
the relative risk for lobular breast cancer in current and ever
HRT users in our patients.
Patients and methods
From 1995 until 2004, 661 cases of primary ductal, lobu-
lar or ductulolobular breast cancer were diagnosed at the
Department of Gynecology and Obstetrics, University
Hospital Basel, Switzerland. All women who were pre-
menopausal (n = 164) by clinical assessment at the time
of diagnosis were excluded. Totally 497 cases of post-
menopausal ductal (n = 398) or lobular/ductulolobular (n
= 99) breast cancer were eligible for this hospital based
study.
Menopause was deWned as the age of the last menstrua-
tion, or the age at bilateral oophorectomy. Women with
unknown age of menopause due to premenopausal hyster-
ectomy were considered as postmenopausal if breast cancer
was diagnosed after the age of 52.
Ever HRT use was deWned as transdermal or oral HRT
use for ¸6 months. If the patient was on HRT for ¸6
months at the time of the diagnosis or ceased HRT ·3
months before the diagnosis of breast cancer she was con-
sidered a current user.
The data considered for the current analysis derived
from patient records, and if missing by telephone interview
(n = 37). We collected data on menstrual, contraceptive
and reproductive history; body size, weight, family history
and personal history of invasive breast cancer or pre-inva-
sive disease, as well as smoking, alcohol consumption, and
history of diabetes. We obtained detailed information
about the use, beginning, cessation, duration and brand of
HRT. The institute of pathology of the University Hospital
Basel provided all histological diagnoses and tumor
characteristics.
Both established and suggested risk factors for breast
cancer were included in the analysis as potential confound-
ing factors, such as age at diagnosis, age at Wrst birth, age at
menopause, the type of menopause (natural, induced by
bilateral oophorectomy, and unknown due to premenopau-
sal hysterectomy), body mass index and family history of
breast cancer.
Statistical analysis
In case of continuous parameters, t test or categorical vari-
ables, Fishers Exact Test was calculated to compare lobular
against ductal cancer (Table 1).
Multiple logistic regression was performed (Table 2) to
detect the inXuence of the parameters age at diagnosis, age
at menopause, HRT, body mass index, family history as
potential confounders and natural or induced menopause on
the two histological subtypes of breast cancer. Odds ratios
(OR) with corresponding 95% conWdence intervals are
reported for all these parameters.
In the case of continuous variables, odds ratio were
expressed as the ratio of the odds from the 3rd to the 1st
quartile of the corresponding distribution.
As body mass index and age at diagnosis show a skew
distribution, a log transformation was applied. A P-value of
<0.05 is considered as signiWcant. All evaluations were cal-
culated with SPSS Version 13.0.
Results
Of the 99 cases of lobular cancer 72.7% (n = 72) were inva-
sive lobular cancer, 21.2% (n = 21) were invasive ductulo-
lobular cancer and 6.1% (n = 6) were lobular cancer in situ.
Of the 398 cases of ductal cancer 90.5% (n = 360) were
invasive ductal cancer and 9.5% (n = 38) were ductal can-
cer in situ.
In our study we had 144 cases of breast cancer in HRT
ever users and 341 cases in HRT never users. Among the
ever users 109 were current and 35 were past users. In 12
cases HRT use remained unknown. The type of HRT (unop-
posed estrogen, estrogen plus progestin, tibolone and proges-
tin) was comparable in ductal and lobular cancers (Table 1).
A comparison of lobular and ductal breast cancer cases
is presented in Table 1 with respect to patients’ and tumor
characteristics.
Ever HRT use was associated with a signiWcantly
increased risk for lobular cancer OR 1.67 (95% CI 1.02–
2.73). Surgical induced menopause due to bilateral oopho-
rectomy was also associated with a signiWcantly increased
risk for lobular cancer OR 2.42 (95% CI 1.06–5.54). Age at
diagnosis of breast cancer, family history for breast cancer,
age at menopause, and body mass index showed no signiW-
cant association to any subtype of breast cancer (Table 2).
All cases were included in the primary analysis. We also
performed a subanalysis of invasive carcinomas excluding all
in situ carcinomas. Bilateral oophorectomy remained associ-
ated with an increased risk for lobular cancer OR 2.32 (95%
CI 1.01–5.33), whereas HRT ever use showed a trend towards
an increased risk for lobular cancer OR 1.57 (95% CI 0.94–
2.63). Another subanalysis was performed by excluding all
women who had undergone premenopausal hysterectomy
without bilateral oophorectomy. Bilateral oophorectomy
showed an increased risk for lobular cancer OR 2.49 (95% CI
1.06–5.86), whereas HRT ever use showed no increased risk
for lobular cancer OR 1.28 (95% CI 0.27–2.27).123
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characteristics, and 
characteristics of menopause 
and hormone replacement 
therapy
Ductal cancer (n = 398) Lobular cancer (n = 99) P
Mean (n) Min–max (%) Mean (n) Min–max (%)
Patients characteristics
Age at diagnosis of breast cancer (in years) 66.98 45–96 66.58 42–94 ns
Age at menarche (in years) 13.56 9–20 13.46 10–19 ns
Age at menopause (in years) 49.99 34–63 50.33 33–63 ns
Age at Wrst birth (in years) 25.65 17–47 26.21 17–46 ns
Parity 1.62 0–6 1.71 0–5 ns
Family history of breast cancer ns
Positive 87 21.9 31 31.3
Negative 300 75.3 65 65.7
Unknown 11 2.8 3 3.0
Body mass index 25.89 16–42 25.83 19–40 ns
Alcohol consumption ns
Never 163 41.0 43 43.5
Regular 227 57.0 53 53.5
Unknown 8 2.0 3 3.0
Smoking ns
Never 315 79.1 71 71.7
Past or current smokers 77 19.4 25 25.3
Unknown 6 1.5 3 3.0
History of diabetes 42 10.6 9 9.1 ns
Tumor characteristics
Tumor size 0.047
In situ 38 9.5 6 6.1
pT1 183 46.0 37 37.4
pT2 120 30.2 36 36.4
pT3 19 4.8 12 12.1
pT4 38 9.5 8 8.0
Lymph nodes ns
Negative 246 61.8 52 52.6
Positive 143 36.0 44 44.4
Nx 9 2.2 3 3.0
Distant disease ns
M0 371 93.2 90 90.9
M1 23 5.8 9 9.1
Mx 4 1.0 0 0.0
Grading 0.005
1 86 21.6 8 8.1
2 194 48.7 59 59.6
3 118 29.7 32 32.3
Estrogens receptor ns
Positive 315 79.1 84 84.9
Negative 77 19.4 13 13.1
Unknown 6 1.5 2 2.0
Progesterone receptor ns
Positive 248 62.3 68 68.7
Negative 144 36.2 29 29.3
Unknown 6 1.5 2 2.0123
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Breast cancer incidence seems to be stable or declining
since 2003 [21, 35]. Up to 2003, however, breast cancer
incidence had been rising in Western countries [24, 25],
and there is evidence that this was more pronounced in lob-
ular breast cancer than in ductal breast cancer.
Li et al. [24] reported a plateau in the incidence of ductal
breast cancer, but an increase in the incidence of lobular
breast cancer between 1987 and 1995 in the US. Two stud-
ies from Switzerland [23, 48] did not report a plateau, but
an increased incidence rate in ductal (0.9–1.2% per year) as
well as lobular (10–14% per year) breast cancer. The
increase, however, was more substantial in lobular breast
cancer. Furthermore, there seem to exist sharp diVerences
in the incidence as well as in the histological subtyping of
breast cancer between diVerent European populations [49].
The rise of HRT use of 38–50% between 1987 and 1992
suggests an association between HRT use and increasing
incidence of lobular breast cancer [5, 9, 18, 24].
Our data show an increased risk for lobular cancer in HRT
ever users OR 1.67 (95% CI 1.02–2.73) and in women after
bilateral oophorectomy OR 2.42 (95% CI 1.06–5.54).
In the primary analysis, where all cases were included,
HRT ever use OR 1.67 (95% CI 1.02–2.73) showed a sig-
niWcant association with lobular cancer. Excluding all
women with in situ carcinomas, a trend towards an
increased risk for lobular cancer in HRT ever users OR
1.57 (95% CI 0.94–2.63) was seen. However, by excluding
women who underwent premenopausal hysterectomy with-
out bilateral oophorectomy, HRT ever users no longer
showed an increased risk for lobular breast cancer OR 1.28
(CI 0.27–2.27). This might be explained by the fact that
these women were usually estrogen HRT ever users.
Other studies are in agreement with our data [28, 31, 34,
36, 49]. Li et al. [24] also included in situ cancers in their
analysis and reported an increased risk for lobular cancer
Table 1 continued Ductal cancer (n = 398) Lobular cancer (n = 99) P
Mean (n) Min–max (%) Mean (n) Min–max (%)
Menopause and hormone replacement therapy
Menopause ns
Natural 286 71.9 68 68.7
History of premenopausal hysterectomy 
without bilateral oophorectomy
92 23.1 21 21.2
Menopause induced by 
bilateral oophorectomy
20 5.0 10 10.1
Hormone replacement therapy 0.026
Never user 282 70.9 59 59.6
Ever user 106 26.6 38 38.4
Unknown 10 2.5 2 2.0
Type of replacement therapy ns
Estrogens plus progestin 50 47.2 20 52.6
Estrogens monotherapy 54 51.0 15 39.5
Tibolon 1 0.9 2 5.3
Progestin 1 0.9 1 2.6
Table 2 Multivariate analysis for factors inXuencing the histological
subtype of breast cancer
a First quartile = 58, third quartile = 65
b First quartile = 47, third quartile = 53
c First quartile = 23, third quartile = 28.6
Reference groups
d HRT ever use, HRT never use
e Natural menopause (women with a history of premenopausal hyster-
ectomy without oophorectomy included), menopause induced by pre-
menopausal bilateral oophorectomy
Ductal 
cancer
Lobular 
cancer
OR 95% CI
Age at diagnosis of 
breast cancera
398 99 1.03 0.70–1.52
Family history for 
breast cancer
387 96 1.5 0.95–2.56
Age at menopauseb 398 99 1.19 0.88–1.62
Body mass indexc 398 99 1.03 0.75–1.41
Hormone replacement 
therapyd
388 97 1.67 1.02–2.73
Type of menopausee 398 99 2.42 1.06–5.54123
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wise, the data of Newcomer et al. [34] showed an increased
risk of lobular breast cancer (OR 1.5; 95% CI 1.1–2.1) in
HRT ever users (estrogen alone and estrogen plus proges-
tin), but not for ductal cancer.
Other authors reported an increased risk for ductal as
well as lobular breast cancer, which was more pronounced
for the latter [13, 17, 26, 33, 37, 45]. The pronounced risk
of lobular breast cancer was seen after combined HRT
(estrogen plus progestin) [17, 26, 33] and estrogen alone
HRT, as well as after combined HRT in other studies [13,
37, 45]. In contrast, other groups did not Wnd evidence that
the eVect of HRT was restricted to or more pronounced in
lobular cancer [47].
While our data show a signiWcant inXuence of surgical
menopause by bilateral oophrectomy on the incidence of
lobular breast cancer [OR 2.42 (95% CI 1.06–5.54)], only a
statistical trend was seen in the work of others [27]. Exclud-
ing all women with in situ carcinomas OR 2.32 (95% CI
1.01–5.33), and all women who underwent premenopausal
hysterectomy without bilateral oophorectomy OR 2.49 (CI
1.06–5.86) bilateral oophorectomy remained associated with
an increased risk for lobular cancer. HRT is frequently pre-
scribed to reduce menopausal symptoms caused by pre-
menopausal bilateral oophrectomy. Therefore, these women
take HRT earlier in life, and for a longer period.
Substantial methodological diVerences between the stud-
ies analyzing the eVects of HRT and certain subtypes of
breast cancer make a comparison of the data very diYcult.
Some authors restricted the age of women included in the
studies to 65 years [17, 28, 31], whereas we and others
include also elderly women [13, 26, 34, 37]. Some studies
compare invasive ductal to lobular cancers [34] while others
compare lobular to nonlobular cancers [13] or ductal to lobu-
lar and to tubular cancers [37]. As in the presented data lobu-
lar and ductulolobular cancers are compared to ductal cancers
[17] and in situ cancers are included in the analysis [28]. In
agreement to our study some authors deWne HRT use if HRT
was used for ¸6 months [13, 28], while others deWne it as ¸3
months [34]. Many studies do not deWne HRT use at all.
A shortcoming of our study is the relatively small num-
ber of breast cancer cases in HRT ever users and the small
number of lobular cancers. The charts did not contain struc-
tured questionnaires, and missing data were obtained by
telephone interview.
In spite of the relatively small numbers of breast cancer
cases in our cohort study, the presented data add to the
growing evidence that HRT might be associated to lobular
breast cancer. This association is of major clinical rele-
vance, since lobular breast cancer is more diYcult to diag-
nose than ductal breast cancer.
Invasive lobular breast cancers are distinguished histo-
logicaly from inWltrating ductal carcinomas by their diVusive
inWltrative pattern that does not destroy the anatomic struc-
tures. They often fail to form distinct masses due to the lack
of a desmoplastic reaction which prevents the lesions from
being clinically and radiologically detected.
As a result, the sensitivity of a physical examination,
including mammography and ultrasound to detect lobular
breast cancer is lower than for the more common ductal
breast cancer [2, 10, 22, 43, 44]. This is also shown by our
data since lobular breast cancer tends to be larger in size
than ductal breast cancer at diagnosis.
Subtle changes that may mimic normal breast paren-
chyma, including opacity similar to that of normal Wbro-
glandular tissue, as well as the common lack of suspicious
microcalciWcations are reasons for the high rate of up to
19% false-negative mammographic diagnosis [6, 20, 22,
39, 42, 44, 52]. In up to 8%, mammograms may even be
completely normal in lobular breast cancer [20, 42, 44].
While ultrasound seems to be more sensitive in detecting
lobular breast cancer than mammography, a false negative
rate of 12.3% has been reported. [6, 10, 20, 42, 44].
HRT increases mammographic breast density and
decreases the sensitivity and speciWcity of mammography
[3, 8, 12, 15, 19, 29, 39] further leaving breast cancer unde-
tected [3, 6–8, 11, 12, 15, 32, 39, 40, 46].
Equivocal clinical, mammographic or sonographic Wnd-
ings in the breasts of women with a history of menopause
induced by oophorectomy, or in past or current HRT users
should lead to further investigations to exclude lobular
breast cancer.
Our data show an increased risk for lobular breast cancer
in ever HRT users and in patients with a history of meno-
pause induced by bilateral oophorectomy. This is relevant
since lobular breast cancer might pose a diagnostic challenge.
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